News

Researchers identified factors that can accurately predict patients with wild-type ATTR-CM who are at high risk of early death.

A study found that tafamidis may reduce levels of a diagnostic marker of ATTR-CM, but the effects appear to plateau over time.

Treatment advances such as RNA silencing and gene-editing technologies offer hope to improve outcomes for patients with ATTR-CM.

Minimal versatile genetic perturbation technology showed promise in addressing genetic diseases such as ATTR-CM.

Researchers found no significant difference in the structure of amyloid fibrils accumulated in different organs in a patient with ATTR-CM.

The tests could detect cardiac nerve fiber abnormalities before symptom onset in ATTR-CM, which could lead to earlier treatment.

Patients with ATTR-CM and destabilizing TTR variants appear to have higher all-cause mortality than patients with stable variants.

Older patients faced a higher prevalence of coexisting cardiac amyloidosis, including ATTR-CM, and coronary artery disease.

Patients with ATTR-CM on vutrisiran had a reduced risk of death and cardiovascular events.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) could have a therapeutic benefit for patients with ATTR-CM.